[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0211438A - Cepas de lactobacillus casei próbióticas - Google Patents

Cepas de lactobacillus casei próbióticas

Info

Publication number
BR0211438A
BR0211438A BR0211438-0A BR0211438A BR0211438A BR 0211438 A BR0211438 A BR 0211438A BR 0211438 A BR0211438 A BR 0211438A BR 0211438 A BR0211438 A BR 0211438A
Authority
BR
Brazil
Prior art keywords
lactobacillus casei
strain
probiotic lactobacillus
casei strains
inflammatory activity
Prior art date
Application number
BR0211438-0A
Other languages
English (en)
Inventor
John Kevin Collins
Gerald Christopher O'sullivan
Liam O'mahony
Fergus Shanahan
Barry Kiely
Original Assignee
Alimentary Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alimentary Health Ltd filed Critical Alimentary Health Ltd
Publication of BR0211438A publication Critical patent/BR0211438A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"CEPAS DE LACTOBACILLUS CASEI PROBIóTICAS". Uma cepa de Lactobacillus casei, ou um mutante ou uma variante da mesma, isolada a partir do trato gastrintestinal humano ressecado e lavado é significativamente imunomodulatória, seguindo-se ao consumo oral em humanos. Em particular, uma cepa de Lactobacillus casei, AH101, AH104, AH111, AH112 ou AH113 ou mutantes ou variantes das mesmas são úteis na profilaxia e/ou no tratamento de atividade inflamatória, especialmente atividade inflamatória gastrintestinal indesejável, tal como uma doença inflamatória do estómago ou síndrome de estómago irritável.
BR0211438-0A 2001-07-26 2002-07-26 Cepas de lactobacillus casei próbióticas BR0211438A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IE20010700 2001-07-26
IE20010699 2001-07-26
IE20010706 2001-07-26
IE20010715 2001-07-26
IE20010712 2001-07-26
PCT/IE2002/000112 WO2003010299A1 (en) 2001-07-26 2002-07-26 Probiotic lactobacillus casei strains

Publications (1)

Publication Number Publication Date
BR0211438A true BR0211438A (pt) 2004-07-13

Family

ID=27517571

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211438-0A BR0211438A (pt) 2001-07-26 2002-07-26 Cepas de lactobacillus casei próbióticas

Country Status (9)

Country Link
US (1) US20030113306A1 (pt)
EP (1) EP1409643A1 (pt)
JP (1) JP2005508150A (pt)
CN (1) CN1556853A (pt)
BR (1) BR0211438A (pt)
CA (1) CA2454805A1 (pt)
IL (1) IL160050A0 (pt)
PE (1) PE20030283A1 (pt)
WO (1) WO2003010299A1 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US7182943B2 (en) * 2002-05-15 2007-02-27 UNIVERSITé LAVAL Method and system for modulation of microbial cell characteristics
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
RU2006107931A (ru) * 2003-08-14 2006-07-27 Дзе Байо Бэлэнс Корпорейшн (Us) Бактериальные штаммы, включающие их композиции и их пробиотическое применение
WO2005030230A1 (en) * 2003-09-30 2005-04-07 Probiomics Limited Compositions and methods for treatment or prevention of psoriasis and related disorders
AU2004275438B2 (en) * 2003-10-01 2008-05-29 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
US8871266B2 (en) * 2003-10-01 2014-10-28 Commonwealth Scientific & Industrial Research Organisation Probiotic storage and delivery
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
EP2270131A1 (en) 2005-05-31 2011-01-05 The Iams Company Feline probiotic lactobacilli
DE602006009144D1 (de) * 2005-11-21 2009-10-22 Bioatlantis Ltd Zusammensetzungen für die verbesserung der darmgesundheit und der tierischen leistung enthaltend beta-glucans and alfa-fucans
ES2551719T3 (es) 2007-02-01 2015-11-23 Iams Europe B.V. Procedimiento para disminuir la inflamación y el estrés en un mamífero usando antimetabolitos de glucosa, aguacate o extractos de aguacate
BRPI0808052A2 (pt) * 2007-02-28 2014-06-24 Mead Johnson Nutrition Co Método para tratar ou prevenir inflamação sistêmica.
CN101144065B (zh) * 2007-09-03 2011-11-09 江南大学 一种耐过氧化氢、清除自由基的抗氧化干酪乳杆菌及其用途
EP2065048A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
WO2010013143A2 (en) * 2008-08-01 2010-02-04 Institut Pasteur Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN102884174B (zh) * 2010-03-26 2016-08-03 株式会社明治 肠道免疫抑制剂的筛选方法
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
WO2013080561A1 (en) 2011-12-01 2013-06-06 University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
WO2014128737A1 (en) * 2013-02-25 2014-08-28 Italchimici S.P.A. Dietary food for the treatment of inflammatory bowel diseases
CN104031855A (zh) * 2013-03-08 2014-09-10 任发政 干酪乳杆菌及其应用以及功能食品组合物及其制备方法
US20150139968A1 (en) * 2013-11-15 2015-05-21 Genmont Biotech Inc. Probiotic composition for treating picornavirus infection and its use thereof
CN104651245B (zh) * 2013-11-15 2017-10-13 景岳生物科技股份有限公司 用于治疗微小核糖核酸病毒感染的益生菌组合物及其用途
US20150209468A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism
WO2015112291A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Filaments comprising a microorganism and method for making same
CN106414708A (zh) 2014-01-24 2017-02-15 宝洁公司 包含含有微生物的纤维元件的纤维网及其制备方法
WO2016008084A1 (zh) * 2014-07-15 2016-01-21 王国全 自体来源乳酸菌的制造方法及系统
US20160354507A1 (en) 2015-06-07 2016-12-08 The Procter & Gamble Company Article of commerce containing absorbent article
JP2018519295A (ja) * 2015-06-22 2018-07-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 粘膜固有層調節性ｔ細胞の誘導
US20170020750A1 (en) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch containing microorganism
CN105087439B (zh) * 2015-08-19 2017-12-12 内蒙古农业大学 一种高抗阿莫西林干酪乳杆菌及其选育方法
CN108135946A (zh) * 2015-08-27 2018-06-08 宝洁公司 长双歧杆菌
TWI598103B (zh) * 2016-08-22 2017-09-11 景岳生物科技股份有限公司 改善困難梭狀桿菌感染症狀的發酵乳酸桿菌ｇｍｎｌ－２９６組合物及方法
JP7228200B2 (ja) * 2017-03-23 2023-02-24 ユニバーシタット アントウェルペン 新規のプロバイオティックなラクトバチルス・カゼイ株及びその使用
AU2017100632A4 (en) * 2017-05-29 2017-07-06 Bgi Shenzhen An oral liquid probiotic formulation and method of preventing and/or treating arthritis
IT201700101704A1 (it) * 2017-09-12 2019-03-12 Sofar Spa Nuovo uso per trattamento delle infezioni da clostridium difficile
CN109486700A (zh) * 2018-08-31 2019-03-19 石家庄君乐宝乳业有限公司 副干酪乳杆菌n1115预防结肠炎的应用及相应的益生菌粉、应用
CN110591950B (zh) * 2019-09-23 2021-05-28 江南大学 一株可以提高肠道il-22表达量的干酪乳杆菌
CN110893195B (zh) * 2019-09-30 2023-03-14 内蒙古伊利实业集团股份有限公司 一种具有缓解肠道炎症功能的副干酪乳杆菌et-22
CN110669697B (zh) * 2019-10-31 2022-07-15 微康益生菌(苏州)股份有限公司 一种高产短链脂肪酸的干酪乳杆菌、培养方法及其应用
CN118020940A (zh) * 2019-11-29 2024-05-14 内蒙古伊利实业集团股份有限公司 副干酪乳杆菌k56提升肠道细菌感染抗性和肠道免疫力的应用
CN112869170B (zh) * 2019-11-29 2023-05-23 伊利伊诺科技(上海)有限责任公司 可提高胃肠道免疫能力的益生菌益生元营养组合物及应用
CN112375722B (zh) * 2021-01-18 2021-04-13 山东中科嘉亿生物工程有限公司 一种改善过敏的干酪乳杆菌lc-12及其产品、应用
CN113088468B (zh) * 2021-04-09 2022-06-03 中国农业大学 干酪乳杆菌Ma.GLRGJ 1及其应用
CN117089505B (zh) * 2023-10-20 2024-03-19 杭州微致生物科技有限公司 一种副干酪乳杆菌vb306及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55113718A (en) * 1979-02-27 1980-09-02 Yakult Honsha Co Ltd Antitumor agent
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection
MXPA99007378A (es) * 1997-02-11 2005-04-19 Entpr Ireland Cepas probioticas de lactobacillus salivarius y agentes antimicrobianos obtenidos a partir de lasmismas.
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
IL156490A0 (en) * 2000-12-18 2004-01-04 Probiohealth Probiotic compounds derived from lactobacillus casei strain ke01

Also Published As

Publication number Publication date
PE20030283A1 (es) 2003-05-01
IL160050A0 (en) 2004-06-20
CA2454805A1 (en) 2003-02-06
US20030113306A1 (en) 2003-06-19
WO2003010299A1 (en) 2003-02-06
CN1556853A (zh) 2004-12-22
EP1409643A1 (en) 2004-04-21
JP2005508150A (ja) 2005-03-31

Similar Documents

Publication Publication Date Title
BR0211438A (pt) Cepas de lactobacillus casei próbióticas
NO20013467D0 (no) Anvendelse av Lactobacillus salivarius
BR0211442A (pt) Cepas de bifidobacterium probióticas
MXPA04000808A (es) Cepas probioticas de lactobacillus salivarius.
EA200101262A1 (ru) Диетическая или фармацевтическая композиция для применения в целях профилактики или лечения гипероксалурии
BR0314060A (pt) Bactéria probiótica: lactobacillus fermentum
WO2008117266A3 (en) Probiotic bifidobacterium strains
BR9916062A (pt) Administração oral de lactobacillus para o tratamento e prevenção de infecção urogenital
ATE534396T1 (de) Probiotische mikroorganismen zur verbesserung der muskulären funktion
ATE409220T1 (de) Lactobacillus-stämme
EE9700269A (et) Farmatseutiline kompositsioon, mis sisaldab Lactobacillus plantarum'it ja arginiini

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2060 DE 29/06/2010.